Relating to abortion, including civil liability for distribution of abortion-inducing drugs; making conforming changes and harmonizing conforming provisions; authorizing a private civil right of action.
HB65 would create a new Chapter 171A in the Health and Safety Code to sharply restrict abortion-inducing drugs in Texas and to create multiple civil enforcement mechanisms. The bill generally prohibits manufacturing, distributing, mailing, transporting, delivering, prescribing, or providing abortion-inducing drugs in the state, subject to exceptions for protected speech, federal preemption, conduct by the pregnant woman herself, medical emergencies, and certain federally directed conduct. It also defines a broad set of terms and expressly states that the chapter is to be known as the Women and Child Protection Act.
The bill’s central feature is a private-enforcement model. It authorizes both direct civil actions and qui tam actions against people who violate the drug restrictions, with statutory damages of at least $100,000 per violation, injunctive relief, and attorney’s fees available to prevailing claimants or relators. It also creates market-share liability if the specific manufacturer cannot be identified, extends the limitations period to six years, bars class actions, and includes venue, jurisdiction, and choice-of-law provisions designed to keep disputes in Texas and under Texas law. The bill further limits defenses, restricts coordinated state involvement in private suits, and creates counterclaim-style remedies against those who sue to block enforcement.
HB65 would also expand the state’s abortion-enforcement framework beyond private suits. It gives the attorney general parens patriae standing to sue on behalf of unborn children of Texas residents for violations of criminal abortion laws, and it adds a fee-shifting provision aimed at discouraging declaratory or injunctive challenges to abortion restrictions or taxpayer-funding limits for abortion providers. Related amendments to the Civil Practice and Remedies Code would carve abortion-enforcement actions out of certain procedural protections and clarify that existing anti-SLAPP and immunity-related provisions do not limit enforcement of abortion restrictions.
The bill’s overall sentiment, based on the text and the absence of recorded committee discussion or votes in the provided materials, appears strongly supportive of abortion restriction and enforcement expansion. The structure of the bill suggests an intent to maximize deterrence and litigation pressure on abortion-drug distribution while insulating the law from judicial and procedural challenges. Because no committee transcript or vote history is provided, there is no recorded in-context opposition or support to summarize beyond the bill’s evident policy direction.
The main points of contention likely would be the breadth of the private-enforcement scheme, the severe damages and fee-shifting provisions, the attempt to limit defenses and venue transfer, and the bill’s efforts to restrict judicial review and state coordination. Potential critics would likely focus on due process, extraterritorial application, First Amendment concerns, federal preemption, and the use of qui tam-style litigation in abortion enforcement, while supporters would likely emphasize fetal protection, deterrence of abortion-drug distribution, and enforcement of existing abortion restrictions.
HB65 would substantially alter Texas law by adding a new abortion-drug enforcement chapter and by amending related civil procedure and health-and-safety provisions to support abortion restriction enforcement. It would create new civil causes of action, authorize private relators and affected parents to sue, expand attorney general authority, and impose special venue, jurisdiction, immunity, and fee-shifting rules that favor enforcement of abortion laws. The bill would affect abortion providers, drug manufacturers and distributors, internet and platform intermediaries only indirectly through express carve-outs, and anyone involved in mailing, transporting, prescribing, or providing abortion-inducing drugs to Texas residents.
The bill’s tone and design indicate strong pro-enforcement, anti-abortion sentiment. It is framed as the Women and Child Protection Act and is built around aggressive civil liability, private enforcement, and procedural barriers to challenges. No committee discussion or votes are included, so there is no recorded legislative debate in the provided materials; however, the text itself reflects a highly assertive approach intended to deter abortion-inducing drug access and litigation against abortion restrictions.
Likely points of contention include the bill’s broad private-right-of-action and qui tam structure, the minimum $100,000 statutory damages, market-share liability, and the attempt to bar class actions and limit defenses. Opponents would likely object to the bill’s extraterritorial reach, its restrictions on judicial review, its fee-shifting against abortion-rights challengers, and its treatment of immunity and venue. Supporters would likely argue that these features are necessary to enforce abortion restrictions effectively and to prevent circumvention through medication abortion, shield laws, or out-of-state conduct.